Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBIT: 2021-2025

Historic EBIT for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $24.0 million.

  • Kiniksa Pharmaceuticals International's EBIT rose 348.72% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year increase of 245.43%. This contributed to the annual value of -$45.6 million for FY2024, which is 81.04% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's EBIT is $24.0 million, which was up 19.15% from $20.2 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBIT peaked at $46.4 million during Q3 2022, and registered a low of -$49.3 million during Q1 2021.
  • For the 3-year period, Kiniksa Pharmaceuticals International's EBIT averaged around -$1.2 million, with its median value being -$3.2 million (2023).
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBIT tumbled by 23,925.93% in 2024 and then spiked by 17,330.77% in 2025.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's EBIT stood at -$36.1 million in 2021, then soared by 116.74% to $6.0 million in 2022, then plummeted by 98.66% to $81,000 in 2023, then crashed by 23,925.93% to -$19.3 million in 2024, then surged by 348.72% to $24.0 million in 2025.
  • Its EBIT was $24.0 million in Q3 2025, compared to $20.2 million in Q2 2025 and $13.3 million in Q1 2025.